# Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

> **NCT02001168** · PHASE3 · UNKNOWN · sponsor: **Xinjiang Medical University** · enrollment: 392 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Docetaxel
- **DRUG:** rh-Endostatin
- **DRUG:** Cis-platinum

## Key facts

- **NCT ID:** NCT02001168
- **Lead sponsor:** Xinjiang Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2020-12
- **Final completion:** 2022-10
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001168, "Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02001168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*